The effect of Sylimarin on insulin resistance and lipid profile in first-degree relatives of diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110116430N2

Enrollment

Registered

2011-10-17

Start date

2011-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First gegree Relatives of Diabetic Patients. Diabetes mellitus

Interventions

Intervention 1: Control group will receive placebo. Intervention 2: Intervention group will cosume 140mg Sylimarin twice a day for 12 weeks.

Placebo

Treatment - Drugs

Control group will receive placebo

Intervention group will cosume 140mg Sylimarin twice a day for 12 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: First-degree relatives of diabetic patients with BMI >25kg/m2 and age>25 years and age<65 year. Exclusion criteria: Diabetic patients or first degree relatives with BMI=<25kg/m2 or who consumed drug or supplementation that reduce insulin resistance for past three months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: inSulin Kit and the Unit is mu/lit.;Lipid profile. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Pars Azmoon kit and the Unit is mg/dl.	—

Secondary

Measure	Time frame
TG. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Pars Azmoon kit.;LDL. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Pars Azmoon kit.;HDL. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Pars Azmoon kit.;Cholesterol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Pars Azmoon kit.;2hpp. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto nalyser method.;FBS. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto nalyser method.	—

Measure

Time frame

TG. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Pars Azmoon kit.;LDL. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Pars Azmoon kit.;HDL. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Pars Azmoon kit.;Cholesterol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Pars Azmoon kit.;2hpp. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto nalyser method.;FBS. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto nalyser method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Bolurani

Yazd Diabetes Research Center, Shahid Sadooghi University of Medical Sciences

saeedbolurani@yahoo.com+98 35 1522 3999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026